Cargando…

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that poses a clinical challenge. Thus, new therapy strategies are urgently needed. The selective WEE1 inhibitor, AZD1775, has shown strong anti-proliferative effects on a variety of tumors. Here, we first demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Juan, Fang, Hehui, Yang, Fang, Ji, Wenfei, Guan, Nan, Sun, Zijia, Shi, Yaqin, Zhou, Guohua, Guan, Xiaoxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915994/ https://www.ncbi.nlm.nih.gov/pubmed/29605721 http://dx.doi.org/10.1016/j.neo.2018.03.003

Ejemplares similares

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors
por: Yang, Fang, et al.
Publicado: (2016)

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
por: Luo, Jiayan, et al.
Publicado: (2016)

Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
por: Rødland, Gro Elise, et al.
Publicado: (2021)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
por: Chien, Wenwen, et al.
Publicado: (2023)

Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2020)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

Differential microRNA expression is associated with androgen receptor expression in breast cancer
por: Shi, Yaqin, et al.
Publicado: (2017)

The ATR-WEE1 kinase module inhibits the MAC complex to regulate replication stress response
por: Wang, Lili, et al.
Publicado: (2021)

PAI‐1 induces Src inhibitor resistance via CCL5 in HER2‐positive breast cancer cells
por: Fang, Hehui, et al.
Publicado: (2018)

WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
por: Xu, Haineng, et al.
Publicado: (2021)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors()
por: Shi, Yaqin, et al.
Publicado: (2019)

ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1
por: Song, Wei, et al.
Publicado: (2017)

The long non‐coding RNA landscape in triple‐negative breast cancer
por: Zhang, Wenwen, et al.
Publicado: (2020)

WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
por: Zheng, Hongping, et al.
Publicado: (2017)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
por: Pitts, Todd M., et al.
Publicado: (2020)

Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer
por: Teo, Zhi Ling, et al.
Publicado: (2023)

Analysis of different HER‐2 mutations in breast cancer progression and drug resistance
por: Sun, Zijia, et al.
Publicado: (2015)

Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib
por: Ji, Wenfei, et al.
Publicado: (2019)

Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
por: Mak, Joyce P.Y., et al.
Publicado: (2014)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
por: Ji, Wenfei, et al.
Publicado: (2020)

Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
por: Chalakur-Ramireddy, Naveen K.R., et al.
Publicado: (2018)

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
por: Xing, Lijie, et al.
Publicado: (2020)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
por: Serra, Violeta, et al.
Publicado: (2022)

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
por: Sørensen, Claus Storgaard, et al.
Publicado: (2012)

Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer
por: Kinose, Yasuto, et al.
Publicado: (2023)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration
por: Chen, Xian, et al.
Publicado: (2021)

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
por: Ha, Dong-Hyeon, et al.
Publicado: (2020)

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Novel therapeutic strategies for patients with triple-negative breast cancer
por: Zhang, Jun-Fei, et al.
Publicado: (2016)

Novel therapeutic strategies in the treatment of triple-negative breast cancer
por: Oualla, Karima, et al.
Publicado: (2017)

Recent advances in therapeutic strategies for triple-negative breast cancer
por: Li, Yun, et al.
Publicado: (2022)

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
por: Li, Ching-Chia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ume8n8infq6581onpvnpl4jn2i